Skip to Content

Isotechnika Inc. completes critical study

EDMONTON, Nov. 22 /CNW/ - Isotechnika Inc. announced today the results
from the rat carcinogenicity study for its lead immunosuppressive drug,
ISA247. ISA247 did not exhibit any carcinogenicity up to the highest doses
tested in male and female rats over a two year period.
     Carcinogenicity studies are required by the United States Food and Drug
Administration (FDA) and other Regulatory Authorities and are a critical part
of the package submitted for marketing approval. Carcinogenicity studies are
performed by administering a range of doses of a drug, including a dose
considerably higher than the anticipated clinical dose for a period of two
years. This timeframe is equivalent to administering the drug over a lifetime
in humans.

     About Isotechnika
     Edmonton-based Isotechnika Inc. is an international biopharmaceutical
company focused on the discovery and development of novel immunosuppressive
therapeutics that are designed to offer advantages over other currently
available treatments. There is a significant unmet medical need in the
treatment of both solid organ transplantation and autoimmune disease. It is
estimated that the market potential exceeds $2 billion annually in sales for
calcineurin inhibitors such as ISA247.
     ISA247 is currently being investigated in a Phase 2b North American trial
for the prevention of kidney graft rejection subsequent to transplantation and
a Phase 3 European/Canadian psoriasis trial.
     Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol "ISA".  More information on Isotechnika can be found

     Partnerships with Isotechnika Inc.
     -  Roche retains an option to continue development of the transplant
        indications based on the successful completion of the ongoing Phase 2b
        kidney transplant trial.

     -  Atrium Medical Corporation has exclusive worldwide licensing agreement
        for use of ISA247 and TAFA93 with drug eluting devices for non-
        systemic treatment of vascular, cardiovascular, target vessel and
        tissue disorders.

     -  Lux Biosciences Inc. was granted worldwide rights to develop and
        commercialize ISA247 for the treatment and prophylaxis of all
        ophthalmic diseases.

     Forward-Looking Statements
     This press release may contain forward-looking statements. Forward
looking statements, including the Company's belief as to the potential of its
products, the Company's expectations regarding the issuance of additional
patents and the Company's ability to protect its intellectual property,
involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the forward
looking statements. Such risks and uncertainties include, among others, the
availability of funds and resources to pursue research and development
projects, the ability to economically manufacture its products, the potential
of its products, the success and timely completion of clinical studies and
trials, the Company's ability to successfully commercialize its products, the
ability of the Company to defend its patents from infringement by third
parties, and the risk that the Company's patents may be subsequently shown to
be invalid or infringe the patents of others. Investors should consult the
Company's quarterly and annual filings with the Canadian commissions for
additional information on risks and uncertainties relating to the forward-
looking statements. Investors are cautioned against placing undue reliance on
forward-looking statements.

     %SEDAR: 00010508E



/For further information: Dr. Robert Foster, Chairman & CEO, Isotechnika
Inc., Phone: (780) 487-1600 (x247), Fax: (780) 484-4105, E-mail:; Stephanie Gillis-Paulgaard, Director, Corporate
Communications, Isotechnika Inc., Phone: (780) 487-1600 (x243), Fax: (780)
484-4105, E-mail:

Posted: November 2007